Skip to main content Back to Top
Advertisement

9/18/2019

Tacrolimus Extended-Release Capsules and Tablets

Products Affected - Description

    • Astagraf XL oral extended release capsule, Astellas, 0.5 mg, 30 count, NDC 00469-0647-73
    • Astagraf XL oral extended release capsule, Astellas, 1 mg, 30 count, NDC 00469-0677-73
    • Astagraf XL oral extended release capsule, Astellas, 5 mg, 30 count, NDC 00469-0687-73

Reason for the Shortage

    • Astellas has Astagraf XL capsules on allocation due to FDA guidance.

Available Products

    • Envarsus XR oral extended release tablet, Veloxis, 0.75 mg, 30 count, NDC 6899-3075-03
    • Envarsus XR oral extended release tablet, Veloxis, 0.75 mg, 100 count, NDC 6899-3075-01
    • Envarsus XR oral extended release tablet, Veloxis, 1 mg, 30 count, NDC 6899-3010-03
    • Envarsus XR oral extended release tablet, Veloxis, 1 mg, 100 count, NDC 6899-3010-01
    • Envarsus XR oral extended release tablet, Veloxis, 4 mg, 30 count, NDC 6899-3040-03
    • Envarsus XR oral extended release tablet, Veloxis, 4 mg, 100 count, NDC 6899-3040-01

Estimated Resupply Dates

    • Astellas has Astagraf XL available on allocation.

Updated

Created September 18, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins